BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...Surveyor Capital, Woodline Partners, Acuta Capital and Driehaus Capital Management, alongside existing investors BVF Partners, Casdin Capital...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...million in a series C round, with participation by new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital...
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...leader, the group includes Lumira Ventures; CCRM Enterprises Holdings Ltd., an affiliate of CCRM; EcoR1 Capital; Casdin Capital...
...Inc.Number of employees: 35Funds raised: $91 millionInvestors: Allogene, Lumira Ventures, CCRM Enterprises Holdings, EcoR1 Capital, Casdin Capital...
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

...fund the deal and are joined by Fidelity Management & Research Co. LLC, Altimeter Capital, Casdin Capital...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

...the two have been investing roughly 70% of their overall venture funding in the sector. Casdin Capital...
...any series, and excludes venture debt.  Source: BioCentury’s BCIQ database Gunjan Ohri OrbiMed Advisors Arch Venture Partners RA Capital Advisors Casdin Capital Surveyor...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

...discount to Beam’s closing price Friday of $113.04. The syndicate included Perceptive Advisors, Farallon Capital, Casdin Capital...
...that could lead to protection from heart attack. Wellington Management led the round alongside co-leader Casdin Capital...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...comment in time for publication. Joining Khosla Ventures in the $40 million round were Perceptive Advisors, Casdin Capital...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...company plans to double its size, hiring about 70 people for its engineering and commercial teams.Casdin Capital...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...$750 million.GV, Arch Venture Partners, Andreessen Horowitz, Casdin Capital...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed Advisors, Casdin Capital...
...Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline...
Items per page:
1 - 10 of 143
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...Surveyor Capital, Woodline Partners, Acuta Capital and Driehaus Capital Management, alongside existing investors BVF Partners, Casdin Capital...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...million in a series C round, with participation by new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital...
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...leader, the group includes Lumira Ventures; CCRM Enterprises Holdings Ltd., an affiliate of CCRM; EcoR1 Capital; Casdin Capital...
...Inc.Number of employees: 35Funds raised: $91 millionInvestors: Allogene, Lumira Ventures, CCRM Enterprises Holdings, EcoR1 Capital, Casdin Capital...
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

...fund the deal and are joined by Fidelity Management & Research Co. LLC, Altimeter Capital, Casdin Capital...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

...the two have been investing roughly 70% of their overall venture funding in the sector. Casdin Capital...
...any series, and excludes venture debt.  Source: BioCentury’s BCIQ database Gunjan Ohri OrbiMed Advisors Arch Venture Partners RA Capital Advisors Casdin Capital Surveyor...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

...discount to Beam’s closing price Friday of $113.04. The syndicate included Perceptive Advisors, Farallon Capital, Casdin Capital...
...that could lead to protection from heart attack. Wellington Management led the round alongside co-leader Casdin Capital...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...comment in time for publication. Joining Khosla Ventures in the $40 million round were Perceptive Advisors, Casdin Capital...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...company plans to double its size, hiring about 70 people for its engineering and commercial teams.Casdin Capital...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...$750 million.GV, Arch Venture Partners, Andreessen Horowitz, Casdin Capital...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed Advisors, Casdin Capital...
...Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline...
Items per page:
1 - 10 of 143